Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
BIBR-1048 is another new oral anticoagulant approved by the US Food and Drug Administration after warfarin. It is a non-peptide thrombin inhibitor that specifically and selectively blocks thrombin. (Free or combined) activity to exert anticoagulant effect. It can be taken orally, is potent, does not require special medication monitoring, and has less drug interactions. It is a major advance in the field of anticoagulation therapy and the field of potentially fatal thrombosis prevention, and it is a milestone. After oral administration and gastrointestinal absorption, it is transformed into dabigatrn with direct anticoagulant activity in the body, which prevents fibrinogen from cleavage into fibrin by binding to the fibrin-specific binding site of thrombin, thereby blocking blood clotting The final step of the waterfall network and thrombosis. It can also dissociate from the fibrin-thrombin conjugate and exert a reversible anticoagulant effect.
Product Categories : API Intermediates > Intermediate for CAS 872728-81-9
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.